Related Experiment Video
Updated: Nov 9, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Strategic targeting of non-small-cell lung cancer utilizing genetic material-based delivery platforms of
Swati Chaudhary1, Amit Singh2,3, Pankaj Kumar2,3
1Department of Applied Sciences, Maharaja Surajmal Institute of Technology, GGSIP University, New Delhi, India.
Abstract:
Several limitations of conventional cancer treatment such as non-specific targeting, solubility problems, and ineffective entry of chemotherapeutics into cancer cells can be overcome by using nanotechnology targeted drug delivery systems. Some combinations of biomolecules and nanoparticles have proven to be excellent therapeutics for Non-small cell lung cancer (NSCLC) in the last decades. Targeted gene delivery has shown in vivo as well as in vitro promising results with therapeutic efficacy. Gene therapy has shown enhanced transfection efficiency and better targeting potential on several NSCLC cell lines. Still, there are several challenges in nanoparticle-mediated gene therapy, which include stability of biomolecules and nanoparticles during delivery, managing their biodistribution, and reducing the possible cytotoxic effects of the nanoparticles, which need to be solved before clinical trials. Evaluation of therapeutic efficacy of biomolecules and nanoparticle combination in gene therapy must be established to expand the application of nano-gene therapy in cancer treatment.
Insights
Nanotechnology offers solutions for cancer treatment limitations, enhancing drug delivery for Non-small cell lung cancer (NSCLC). Further research is needed to address challenges in nanoparticle-mediated gene therapy before clinical application.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Conventional cancer treatments face limitations including poor targeting, solubility issues, and inefficient drug entry into cancer cells.
- Nanotechnology-based targeted drug delivery systems present a promising approach to overcome these challenges.
- Biomolecule-nanoparticle combinations have shown potential as therapeutics for Non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To explore the potential of nanotechnology-mediated targeted drug delivery for overcoming limitations in conventional cancer treatments.
- To review the efficacy of biomolecule-nanoparticle combinations in Non-small cell lung cancer (NSCLC) therapy.
- To identify challenges and future directions for nanoparticle-mediated gene therapy in cancer treatment.
Main Methods:
- Review of existing literature on nanotechnology applications in cancer therapy.
- Analysis of studies investigating biomolecule-nanoparticle combinations for Non-small cell lung cancer (NSCLC).
- Evaluation of gene therapy approaches utilizing nanoparticles for enhanced transfection and targeting.
Main Results:
- Nanoparticle-targeted drug delivery systems show promise in overcoming limitations of conventional cancer therapies.
- Gene therapy combined with nanoparticles demonstrates enhanced transfection efficiency and targeting potential in NSCLC cell lines.
- In vivo and in vitro studies indicate promising therapeutic efficacy for targeted gene delivery.
Conclusions:
- Nanoparticle-mediated targeted drug delivery holds significant potential for advancing cancer treatment, particularly for NSCLC.
- Challenges such as biomolecule/nanoparticle stability, biodistribution control, and cytotoxicity must be addressed for clinical translation.
- Further evaluation of the therapeutic efficacy of biomolecule-nanoparticle combinations is crucial for expanding nano-gene therapy applications.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
